These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 1739178)
21. Palliation of gastric outlet obstruction and proximal small bowel obstruction with self-expandable metal stents: a single center series. Mosler P; Mergener KD; Brandabur JJ; Schembre DB; Kozarek RA J Clin Gastroenterol; 2005 Feb; 39(2):124-8. PubMed ID: 15681907 [TBL] [Abstract][Full Text] [Related]
22. The role of octreotide in malignant bowel obstruction. Krammer LM Oncol Nurs Forum; 1999 Jun; 26(5):831-2. PubMed ID: 10382174 [No Abstract] [Full Text] [Related]
23. Octreotide improved the quality of life in a child with malignant bowel obstruction caused by peritoneal dissemination of colon cancer. Watanabe H; Inoue Y; Uchida K; Okugawa Y; Hiro J; Ojima E; Kobayashi M; Miki C; Kusunoki M J Pediatr Surg; 2007 Jan; 42(1):259-60. PubMed ID: 17208578 [TBL] [Abstract][Full Text] [Related]
24. Identification of a safe site for percutaneous endoscopic gastrostomy placement in patients with marked bowel distension: may octreotide have a role? Sartori S; Trevisani L; Nielsen I; Tassinari D; Righini E Endoscopy; 1994 Oct; 26(8):710-1. PubMed ID: 7859687 [No Abstract] [Full Text] [Related]
25. How to use octreotide for malignant bowel obstruction. Ripamonti C; Mercadante S J Support Oncol; 2004; 2(4):357-64. PubMed ID: 15357519 [No Abstract] [Full Text] [Related]
26. Clinical impact of palliative treatment using octreotide for inoperable malignant bowel obstruction caused by advanced urological cancer. Kubota H; Taguchi K; Kobayashi D; Naruyama H; Hirose M; Fukuta K; Kubota Y; Yasui T; Yamada Y; Kohri K Asian Pac J Cancer Prev; 2013; 14(12):7107-10. PubMed ID: 24460259 [TBL] [Abstract][Full Text] [Related]
27. Practice Patterns of Medications for Patients With Malignant Bowel Obstruction Using a Nationwide Claims Database and the Association Between Treatment Outcomes and Concomitant Use of H Minoura T; Takeuchi M; Morita T; Kawakami K J Pain Symptom Manage; 2018 Feb; 55(2):413-419.e2. PubMed ID: 29122616 [TBL] [Abstract][Full Text] [Related]
28. Octreotide prevents the pathological alterations of bowel obstruction in cancer patients. Mercadante S; Avola G; Maddaloni S; Salamone G; Aragona F; Rodolico V Support Care Cancer; 1996 Sep; 4(5):393-4. PubMed ID: 8883235 [No Abstract] [Full Text] [Related]
29. Scopolamine butylbromide plus octreotide in unresponsive bowel obstruction. Mercadante S J Pain Symptom Manage; 1998 Nov; 16(5):278-80. PubMed ID: 9846021 [No Abstract] [Full Text] [Related]
30. Treatment of external biliary, pancreatic and intestinal fistulas with a somatostatin analog. Kocak S; Bumin C; Karayalcin K; Alacayir I; Aribal D Dig Dis; 1994; 12(1):62-8. PubMed ID: 8200125 [TBL] [Abstract][Full Text] [Related]
31. Palliative care for intestinal obstruction in recurrent ovarian cancer: a multivariate analysis. Mangili G; Aletti G; Frigerio L; Franchi M; Panacci N; Viganò R; DE Marzi P; Zanetto F; Ferrari A Int J Gynecol Cancer; 2005; 15(5):830-5. PubMed ID: 16174232 [TBL] [Abstract][Full Text] [Related]
32. Malignant irreversible intestinal obstruction: the powerful association of octreotide to corticosteroids, antiemetics, and analgesics. Weber C; Zulian GB Am J Hosp Palliat Care; 2009; 26(2):84-8. PubMed ID: 19088264 [TBL] [Abstract][Full Text] [Related]